These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37808274)

  • 1. Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis.
    Kivitz A; Ellis AM; Shende V; Lambert J; Tatla D
    Patient Prefer Adherence; 2023; 17():2451-2461. PubMed ID: 37808274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.
    Bagel J; Tatla D; Hellot S; Knapp B; Murphy C; Peterson L; Sebastian M
    J Drugs Dermatol; 2022 Feb; 21(2):162-171. PubMed ID: 35133113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
    Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
    Mease PJ; Merola JF; Tanaka Y; Gossec L; McInnes IB; Ritchlin CT; Landewé RBM; Asahina A; Ink B; Heinrichs A; Bajracharya R; Shende V; Coarse J; Coates LC
    Rheumatol Ther; 2024 Oct; 11(5):1363-1382. PubMed ID: 39215949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
    Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
    Coates LC; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Orbai AM; Gottlieb AB; Warren RB; Ink B; Bajracharya R; Shende V; Coarse J; Merola JF
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38388171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
    Ritchlin CT; Kavanaugh A; Merola JF; Schett G; Scher JU; Warren RB; Gottlieb AB; Assudani D; Bedford-Rice K; Coarse J; Ink B; McInnes IB
    Lancet; 2020 Feb; 395(10222):427-440. PubMed ID: 32035552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies.
    McInnes IB; Mease PJ; Tanaka Y; Gossec L; Husni ME; Kristensen LE; Warren RB; Ink B; Bajracharya R; Coarse J; Gottlieb AB
    ACR Open Rheumatol; 2024 Nov; 6(11):720-731. PubMed ID: 39077886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
    Glatt S; Baeten D; Baker T; Griffiths M; Ionescu L; Lawson ADG; Maroof A; Oliver R; Popa S; Strimenopoulou F; Vajjah P; Watling MIL; Yeremenko N; Miossec P; Shaw S
    Ann Rheum Dis; 2018 Apr; 77(4):523-532. PubMed ID: 29275332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bimekizumab for the treatment of psoriatic arthritis.
    Tanaka Y; Shaw S
    Expert Rev Clin Immunol; 2024 Feb; 20(2):155-168. PubMed ID: 37909894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
    Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
    Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
    Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
    JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
    Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
    J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bimekizumab for the treatment of psoriatic disease.
    Natsis NE; Gottlieb AB
    Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
    Ali Z; Matthews R; Al-Janabi A; Warren RB
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1073-1081. PubMed ID: 34384327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
    Reis J; Vender R; Torres T
    BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.
    Mease PJ; Asahina A; Gladman DD; Tanaka Y; Tillett W; Ink B; Assudani D; de la Loge C; Coarse J; Eells J; Gossec L
    Rheumatology (Oxford); 2023 Feb; 62(2):617-628. PubMed ID: 35789257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.